This trial will compare the effectiveness and safety of co-formulated pembrolizumab/quavonlimab with other treatments for people with MSI-H or dMMR metastatic stage IV colorectal cancer.
1 Primary · 10 Secondary · Reporting Duration: Up to approximately 50 months
Active Control
Experimental Treatment
320 Total Participants · 5 Treatment Groups
Primary Treatment: Pembrolizumab/Quavonlimab · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Nova Scotia | 100.0% |
18 - 65 | 100.0% |
The Moncton Hospital-Oncology ( Site 0307) | 100.0% |
Met criteria | 100.0% |